Regeneron Pharmaceuticals (REGN) Stock Price, Quote & News

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul...

Industry: Biotechnology

Sector: Healthcare

Phone: 914 847 7000

Website: www.regeneron.com

Address:

777 Old Saw Mill River Road, Tarrytown, United States

DidYouReadThis Sep. 4 at 12:23 AM

$REGN

0 · Reply

DidYouReadThis Sep. 3 at 10:44 PM

#Eyecare #Healthcare #FDAApproved Is the parent #molecule of ranibizumab=bevacizumab? $REGN #congrats for the #win #in2006 during the #presidency of #President #George #Bush, and $OTLK #congrats #forthewin #in2026 during the #presidency of #President #Donald #Trump! #GeorgeBush #DonaldTrump #FDA #Gov #government Do #you think #affordable bevacizumab’s #approval for wet age related macular degeneration is a win for #patients, #doctors, #Medicare, #Medicaid, #USA, #UnitedStates, #seniors, #insurers, #insurance, and #families?

0 · Reply

focafoca99 Sep. 3 at 2:16 PM

$REGN faces a securities class action alleging misleading trial disclosures.

2 · Reply

OffHisGame88 Sep. 2 at 6:21 PM

$REGN $1000 this year

0 · Reply

Stocktwits52wHighs Sep. 2 at 6:01 PM

$REGN printed a new 52-week high today

1 · Reply

moneybag888 Sep. 2 at 5:14 PM

$REGN $906 gap? 🙌🚀

0 · Reply

moneybag888 Sep. 2 at 4:57 PM

$REGN new 52w HIGH $ARGX

0 · Reply

Tom2772 Sep. 2 at 3:22 PM

$OTLK $COR $REGN And the insider buying over the past few weeks deserves attention. 👀 2,772,165 shares bought for roughly $2.75M by GMS Ventures, CEO Robert Jahr and Director Faisal Ghiath Sukhtian. Plus 2,676,767 warrants at $1.10 attached to the GMS/CEO purchases. Insiders were willing to put millions into $OTLK at $0.99–$1.0482 while the stock is now trading around $0.61. Are they stupid… or do they know exactly what they’re buying? 👀

2 · Reply

Tom2772 Sep. 2 at 2:57 PM

$OTLK $COR $REGN ~$152M market cap. ~$0.61/share. ~$62M cash. FDA approval secured. A commercial product. Expected 12-year U.S. reference product exclusivity. European commercialization underway. Cencora already in place as a strategic U.S. launch partner. U.S. launch targeted for year-end 2026. $50–75M expected revenue in the first 12 months and a >$500M annual U.S. sales base-case target before 2030. These are the kind of prospects biotech companies dream about BEFORE FDA approval. $OTLK already has the approval, product, cash, market, strategic partner and potentially 12 years of U.S. exclusivity. The valuation simply doesn’t seem to reflect what is already in place. LOL

0 · Reply

handmedown1 Sep. 1 at 10:47 PM

$REGN $CRSP if only.. one day

1 · Reply

Regeneron Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference

Aug 25, 2026, 10:41 AM EDT - 15 days ago

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN

2026-08-21T11:58:53.000Z - 19 days ago

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims

Aug 19, 2026, 4:05 PM EDT - 21 days ago

Regeneron Announces Investor Conference Presentations

Aug 19, 2026, 2:17 PM EDT - 21 days ago

US FDA approves Regeneron's rare bone disorder drug

Aug 19, 2026, 1:58 PM EDT - 21 days ago

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

2026-08-17T10:15:09.000Z - 23 days ago

Regeneron price target raised to $824 from $641 at Leerink

2026-08-06T15:35:28.000Z - 4 weeks ago

Regeneron announces Health Canada approval of new indication for Libtayo

2026-08-03T13:30:28.000Z - 5 weeks ago

Regeneron price target raised to $1,030 from $1,000 at Guggenheim

Aug 3, 2026, 7:05 AM EDT - 5 weeks ago

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg

2026-08-03T10:41:45.000Z - 5 weeks ago

Regeneron price target raised to $740 from $700 at Citi

2026-07-31T14:05:59.000Z - 5 weeks ago

Regeneron price target raised to $737 from $696 at RBC Capital

SNY

2026-07-31T13:11:01.000Z - 5 weeks ago

Regeneron price target raised to $758 from $730 at Morgan Stanley

2026-07-31T13:01:58.000Z - 5 weeks ago

Regeneron price target raised to $891 from $856 at BofA

2026-07-31T12:37:44.000Z - 5 weeks ago

Regeneron price target raised to $795 from $750 at Cantor Fitzgerald

2026-07-31T11:25:46.000Z - 5 weeks ago

Regeneron price target raised to $761 from $742 at Baird

Jul 31, 2026, 7:00 AM EDT - 5 weeks ago

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

2026-07-31T10:20:46.000Z - 5 weeks ago

Regeneron price target raised to $750 from $700 at Wells Fargo

Jul 30, 2026, 8:30 AM EDT - 5 weeks ago

Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 5 weeks ago

Regeneron Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 5 weeks ago

Regeneron Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:30 AM EDT - 5 weeks ago

Regeneron Pharmaceuticals Slides: Q2 2026

2026-07-30T12:21:28.000Z - 5 weeks ago

Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B

Jul 30, 2026, 7:54 AM EDT - 5 weeks ago

Regeneron beats quarterly estimates on eczema drug strength, shares rise

2026-07-30T10:35:57.000Z - 5 weeks ago

Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20

Jul 30, 2026, 6:30 AM EDT - 5 weeks ago

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Jul 29, 2026, 10:27 PM EDT - 6 weeks ago

REGN Stockholders Have Rights – If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Jul 24, 2026, 1:40 PM EDT - 6 weeks ago

The Scientist With 1,000 Patents Fueling a Drug Powerhouse

Jul 24, 2026, 6:36 AM EDT - 6 weeks ago

$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law

Jul 21, 2026, 4:03 PM EDT - 7 weeks ago

REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law

2026-07-21T12:06:20.000Z - 7 weeks ago

Regeneron price target raised to $1,000 from $995 at Guggenheim

Jul 20, 2026, 2:42 PM EDT - 7 weeks ago

REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2026-07-20T11:35:36.000Z - 7 weeks ago

Biohaven enters into clinical supply agreement with Regeneron

BHVN

Jul 15, 2026, 1:20 PM EDT - 1 month ago

Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings

BKNG GOOG GOOGL PAYC PAYX SYK EVR

Jun 29, 2026, 3:03 PM EDT - 2 months ago

FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports

LLY

Jun 29, 2026, 2:50 PM EDT - 2 months ago

Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities

LLY

Jun 25, 2026, 4:05 PM EDT - 2 months ago

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Jun 22, 2026, 7:00 AM EDT - 2 months ago

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Jun 12, 2026, 10:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Transcript: AGM 2026

Jun 12, 2026, 10:30 AM EDT - 2 months ago

Regeneron Pharmaceuticals Slides: FY 2026

Jun 8, 2026, 2:00 PM EDT - 3 months ago

Regeneron Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 7:00 AM EDT - 3 months ago

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

May 28, 2026, 4:00 PM EDT - 3 months ago

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

May 25, 2026, 11:31 AM EDT - 3 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

May 22, 2026, 7:00 AM EDT - 3 months ago

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

May 21, 2026, 5:01 PM EDT - 3 months ago

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

May 18, 2026, 3:25 PM EDT - 3 months ago

Regeneron stock drops double digits on oncology trial failure

May 18, 2026, 7:28 AM EDT - 3 months ago

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda

May 18, 2026, 7:04 AM EDT - 3 months ago

Regeneron Shares Slide Premarket after Melanoma Drug Trial Disappoints

May 18, 2026, 7:00 AM EDT - 3 months ago

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

May 18, 2026, 7:00 AM EDT - 3 months ago

Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

May 18, 2026, 5:57 AM EDT - 3 months ago

Regeneron drops after skin cancer treatment misses late-stage trial goal

May 15, 2026, 8:19 PM EDT - 3 months ago

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

May 15, 2026, 5:56 PM EDT - 3 months ago

UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

May 15, 2026, 4:27 PM EDT - 3 months ago

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

May 12, 2026, 1:00 PM EDT - 4 months ago

Regeneron Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 7:00 AM EDT - 4 months ago

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

May 5, 2026, 7:00 AM EDT - 4 months ago

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Apr 29, 2026, 8:30 AM EDT - 4 months ago

Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 4 months ago

Regeneron Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 4 months ago

Regeneron Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 4 months ago

Regeneron Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 7:43 AM EDT - 4 months ago

Regeneron beats quarterly results estimates on strong Dupixent demand

DidYouReadThis Sep. 4 at 12:23 AM

$REGN

0 · Reply

DidYouReadThis Sep. 3 at 10:44 PM

0 · Reply

focafoca99 Sep. 3 at 2:16 PM

$REGN faces a securities class action alleging misleading trial disclosures.

2 · Reply

OffHisGame88 Sep. 2 at 6:21 PM

$REGN $1000 this year

0 · Reply

Stocktwits52wHighs Sep. 2 at 6:01 PM

$REGN printed a new 52-week high today

1 · Reply

moneybag888 Sep. 2 at 5:14 PM

$REGN $906 gap? 🙌🚀

0 · Reply

moneybag888 Sep. 2 at 4:57 PM

$REGN new 52w HIGH $ARGX

0 · Reply

Tom2772 Sep. 2 at 3:22 PM

2 · Reply

Tom2772 Sep. 2 at 2:57 PM

0 · Reply

handmedown1 Sep. 1 at 10:47 PM

$REGN $CRSP if only.. one day

1 · Reply

Game_Day Sep. 1 at 2:43 PM

SEP 1 on watch $REGN $AMT $MRNA $WELL

0 · Reply

Iwannagofast1 Sep. 1 at 1:56 PM

$REGN Only stock long in biotech. I said I will sell at $900-1000 and we’re getting there !!!

0 · Reply

DidYouReadThis Aug. 31 at 7:51 PM

$PPH What’s closest to when you predict there might be anything firm announced related to compounded bevacizumab for wet AMD, given the FDA approval of #OutlookTherapeutic’s ophthalmic bevacizumab won approval for wet AMD 7/24/26? $OTLK $REGN $NVS #eyecare #healthcare

0 · Reply

Quantumup Aug. 31 at 12:48 PM

Guggenheim⬆️ $KYMR's PT to $170 from $135 and keeps at Buy $REGN - SNY APGE - ABBV $CRVS NKTR GSK AUPH NVS RHHBY Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2094406655504973857?s=20

0 · Reply

DidYouReadThis Aug. 30 at 7:00 PM

What’s closest to your #preferred #tempo of #pharma or #biotech #commercials #ads #ad #commercial ? $ABBV $REGN $NVS $OTLK #HEALTHCARE

0 · Reply

DidYouReadThis Aug. 28 at 8:02 PM

Does $OTLK share price action post FDA approval remind you more of $AXSM or $BLUE or $REGN ? Did BLUE go private 14 months after approval? Do you think $OTLK might be higher by #DollyPartonDay next year 9/25/27? #ninetofive

0 · Reply

moneybag888 Aug. 28 at 6:45 PM

$REGN

0 · Reply

TalkMarkets Aug. 28 at 4:27 PM

The VRTX–REGN Divergence: Growth Efficiency Vs. Scale Premium $VRTX $REGN https://talkmarkets.com/article/the-vrtxregn-divergence-growth-efficiency-vs-scale-premium-1787934411

0 · Reply

tradehulk Aug. 28 at 1:20 PM

$REGN $NXPI ⚡ BREAKING: Core AI Holdings delivers a stellar Q2 with revenue up 56%! 📊💰

0 · Reply

focafoca99 Aug. 27 at 2:20 PM

$REGN legal notice: securities class action filed against Regeneron.

0 · Reply

DidYouReadThis Aug. 26 at 6:21 PM

$REGN $BAYRY $OTLK can anyone please #factcheck? https://www.managedhealthcareexecutive.com/view/bevacizumab-surpasses-eylea-as-the-most-common-retinal-disease-injection-asrs-2026

0 · Reply

DidYouReadThis Aug. 26 at 6:02 PM

Who has the best #constipation #solution #otc? $BAYRY $LLY $REGN $NVS Can #pennystocks cause #constipation?

0 · Reply

Market Cap	83.43B
Revenue (ttm)	14.34B
Net Income (ttm)	4.50B
EPS (ttm)	N/A
PE Ratio	21.25
Forward PE	18.70
Profit Margin	31.41%
Debt to Equity Ratio	0.06

Volume	621,400
Avg Vol	749,662
Day's Range	N/A - N/A
Shares Out	102.96M
Stochastic %K	36%
Beta	0.20
Analysts	Strong Sell
Price Target	$852.18